Drug Trial Radar · NCT06588686
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
378
Actual
Start
Dec 9, 2024
Primary completion
May 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- Vicore Pharma ABIndustry
- Sponsor type
- Industry
- Collaborators
- Population Services International
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF. Trial website: www.aspire-ipf.com
Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
Interventions
BuloxibutidDrug
Buloxibutid
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the efficacy of buloxibutid compared to placebo in participants with IPF as assessed by FVCTime frame: week 52
Locations
104 sites in 14 countries. Site status is shown where the registry gives one.
UAB Hospital, School of Medicine/Lung Health Center
Birmingham, Alabama
Paradigm Clinical Research Centers, Inc.
Redding, California
UC Davis Health System
Sacramento, California
UC San Diego Medical Center - Hillcrest
San Diego, California
Paradigm Clinical Research
San Diego, California
National Jewish Medical and Research Center
Denver, Colorado
University of Florida Health (UF Health)
Gainesville, Florida
Clinical Research Specialists
Kissimmee, Florida
Emory Saint Joseph's Hospital
Atlanta, Georgia
Endeavor Health - Evanston Hospital
Evanston, Illinois
University of Kansas Medical Center
Kansas City, Kansas
William Beaumont Hospital - Royal Oak
Royal Oak, Michigan
Renown Clinical Research
Reno, Nevada
Southeastern Research Center
Winston-Salem, North Carolina
Cleveland Clinic - Cleveland, Department of Pulmonary Medicine
Cleveland, Ohio
Summit Health - Bend
Bend, Oregon
Oregon Clinic, Pulmonary, Critical Care & Sleep Medicine East
Portland, Oregon
Temple University Hospital
Philadelphia, Pennsylvania
Low Country Lung and Critical Care
North Charleston, South Carolina
Baylor Scott & White Research Institute
Dallas, Texas
El Paso Pulmonary Association
El Paso, Texas
University of Utah, Health Sciences Center
Salt Lake City, Utah
University of Wisconsin Clinical Science Center
Madison, Wisconsin
CEMER Medical Center for Respiratory Diseases
Buenos Aires, Argentina
Belgrano Clinical Research Center
Buenos Aires, Argentina
CINME - Metabolic Research Center
Buenos Aires, Argentina
Medical Center Dra. De Salvo
Buenos Aires, Argentina
IMER Respiratory Medicine Institute
Córdoba, Argentina
Breathe Comprehensive Clinical Health
Godoy Cruz, Argentina
Emphysema Foundation, Pneumology
Mar del Plata, Argentina
Vistalba Health Center
Mendoza, Argentina
Ibamedica
Santa Fe, Argentina
InnovaCiencia
Rosario, Rosario, Argentina
Research Institute of Respiratory Diseases
San Miguel de Tucumán, Tucumán Province, Argentina
Flinders Medical Centre
Adelaide, Australia
The Prince Charles Hospital
Brisbane, Australia
Concord Repatriation General Hospital, Department of Respiratory Medicine
Concord, Australia
St Vincent's Hospital, Sydney Ltd.
Darlinghurst, Australia
Townsville University Hospital
Douglas, Australia
Austin Hospital
Heidelberg, Australia
Showing 40 of 104 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.